Furthermore, our results suggest that the EGFR inhibitor gefitinib has the potential to reverse regorafenib resistance, offering significant clinical value for the treatment of regorafenib-resistant patients with HCC. This evidence concerns the gene EGFR and hepatocellular carcinoma.